Browsing Tag
Enhertu
28 posts
Avacta’s (AIM: AVCT) AVA6103 human data: What is proven before the 2027 efficacy test?
Avacta has reported preliminary controlled-release evidence from 19 patients treated with AVA6103, but tumour-selective delivery and clinical efficacy remain unconfirmed. Its latest ÂŁ12.5 million financing places additional attention on the anticipated 2027 results.
Avacta wins pre|CISION R&D award, but AVA6103’s H1 2027 efficacy test matters more
Avacta Group plc has moved AVA6103 into its fourth Phase 1 dose level after early human data supported the intended controlled-release mechanism of its pre|CISION platform. The next valuation test is shifting from pharmacokinetic validation to whether higher payload exposure produces meaningful antitumour activity.
Avacta AVA6103 clears clinical mechanism hurdle as 2027 efficacy test moves into focus
Avacta Group’s first human AVA6103 data show controlled exatecan release and encouraging tolerability at doses above conventional exatecan’s published maximum tolerated level, strengthening the preCISION platform thesis while leaving clinical efficacy as the next decisive test.
Avacta (AIM: AVCT) just paid down ÂŁ3.67m of bond debt in cash. The real question is what AVA6103 does next.
Avacta cleared bond debt in cash and reaches its AVA6103 readout on funded runway. The next six months decide whether pre|CISION reads as one drug or a platform.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: ÂŁ16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, ÂŁ16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications
Enhertu is moving from late-stage control to early-stage cure. AstraZeneca and Daiichi Sankyo now face the bigger test: adoption.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
Aditxt eyes Pearsanta IPO and oncology pivot as ADTX (NASDAQ) tests retail patience
Aditxt regained Nasdaq compliance, then filed to issue 148 million shares. ADTX retail investors are watching Pearsanta's IPO and a bitXbio crypto pivot.